You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
McKinsey
Merck
Moodys
Harvard Business School

Last Updated: April 18, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZORVOLEX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ZORVOLEX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03304379 Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip Not yet recruiting Regeneron Pharmaceuticals Phase 3 2017-10-20 The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: to evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with OA of the knee or hip; to assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with OA of the knee or hip
NCT03949673 Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip Enrolling by invitation Teva Pharmaceutical Industries, Ltd. Phase 2 2019-04-08 The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo or Non-steroidal anti-inflammatory drugs (NSAIDs).
NCT03949673 Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip Enrolling by invitation Regeneron Pharmaceuticals Phase 2 2019-04-08 The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo or Non-steroidal anti-inflammatory drugs (NSAIDs).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZORVOLEX

Condition Name

Condition Name for ZORVOLEX
Intervention Trials
Osteoarthritis, Knee 2
Osteoarthritis, Hip 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZORVOLEX
Intervention Trials
Osteoarthritis, Knee 2
Osteoarthritis, Hip 2
Osteoarthritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZORVOLEX

Trials by Country

Trials by Country for ZORVOLEX
Location Trials
United States 20
United Kingdom 12
Poland 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ZORVOLEX
Location Trials
Nebraska 1
Alabama 1
New Mexico 1
New York 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZORVOLEX

Clinical Trial Phase

Clinical Trial Phase for ZORVOLEX
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZORVOLEX
Clinical Trial Phase Trials
Enrolling by invitation 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZORVOLEX

Sponsor Name

Sponsor Name for ZORVOLEX
Sponsor Trials
Regeneron Pharmaceuticals 2
Teva Pharmaceutical Industries, Ltd. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZORVOLEX
Sponsor Trials
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
Dow
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.